- ISIN
- US1523091007
- CUSIP
- 152309100
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 28, 2021
Highlights
- EPS (TTM)
- -$1.81
- Total Revenue (TTM)
- $15.00M
- Gross Profit (TTM)
- $15.00M
- EBITDA (TTM)
- -$227.27M
- Year Range
- $12.74 - $40.26
- Target Price
- $38.60
- ROA (TTM)
- -35.30%
- ROE (TTM)
- -46.06%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CNTA Performance Chart
Centessa Pharmaceuticals Limited (CNTA) is up 60.7% since the beginning of the year. At $40 per share, CNTA is currently trading at its 52-week high. Investors who bought $1,000 worth of CNTA shares 5 years ago would now be looking at an investment worth $1,689.
Loading charts...
Returns By Period
Centessa Pharmaceuticals Limited (CNTA) has returned 60.66% so far this year and 223.25% over the past 12 months.
Centessa Pharmaceuticals Limited
- 1D
- 0.40%
- 1M
- 1.08%
- YTD
- 60.66%
- 6M
- 58.31%
- 1Y
- 223.25%
- 3Y*
- 82.59%
- 5Y*
- 11.05%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CNTA Monthly Returns History
Based on dividend-adjusted daily data since May 28, 2021, CNTA's average daily return is +0.16%, while the average monthly return is +2.63%. At this rate, an investment would double in approximately 2.2 years.
Historically, 52% of months were positive and 48% were negative. The best month was Mar 2026 with a return of +47.9%, while the worst month was May 2022 at -48.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, CNTA closed higher 49% of trading days. The best single day was Mar 31, 2026 with a return of +44.0%, while the worst single day was Jun 2, 2022 at -27.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.76% | 9.32% | 47.88% | -0.76% | 0.86% | 1.06% | 60.66% | ||||||
| 2025 | 1.01% | -8.10% | -7.52% | -4.66% | -1.46% | -2.74% | 30.67% | -2.21% | 44.43% | 2.68% | 16.59% | -13.85% | 49.31% |
| 2024 | 2.89% | 28.33% | 7.52% | -18.94% | -5.79% | 4.63% | 16.61% | 28.21% | 18.44% | -5.94% | 19.08% | -6.48% | 110.43% |
| 2023 | 29.03% | -12.00% | 9.38% | 22.60% | -4.45% | 37.25% | 27.63% | -4.56% | -14.19% | 1.55% | -8.68% | 32.67% | 156.77% |
| 2022 | -15.36% | -6.40% | 0.56% | -2.79% | -48.39% | 8.22% | -11.29% | 0.69% | -7.59% | -1.24% | 0.76% | -22.50% | -72.47% |
| 2021 | 7.41% | 2.11% | -7.07% | 6.83% | -24.26% | 2.99% | -31.10% | -4.98% | -44.40% |
Benchmark Metrics
Centessa Pharmaceuticals Limited has an annualized alpha of 29.64%, beta of 1.03, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 28, 2021.
- This stock captured 189.85% of S&P 500 Index gains and 159.02% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 29.64%
- Beta
- 1.03
- R²
- 0.06
- Upside Capture
- 189.85%
- Downside Capture
- 159.02%
Return for Risk
Risk / Return Rank
CNTA ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Centessa Pharmaceuticals Limited (CNTA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CNTA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.37 | ||
| Sortino ratioReturn per unit of downside risk | +2.52 | ||
| Omega ratioGain probability vs. loss probability | 1.69 | 1.37 | +0.33 |
| Calmar ratioReturn relative to maximum drawdown | 8.52 | 2.78 | +5.74 |
| Martin ratioReturn relative to average drawdown | 23.60 | 12.44 | +11.16 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Centessa Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Centessa Pharmaceuticals Limited was 88.19%, occurring on Feb 16, 2023. Recovery took 687 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -88.19%Feb 2023 | 1y 8mo | 2y 9mo | 4y 4moJun 2021 - Nov 2025 |
2026 bear market2026 | -26.38%Jan 2026 | 1mo 5d | 2mo 18d | 3mo 23dDec 2025 - Mar 2026 |
2021 correction2021 | -13.54%Jun 2021 | 8d | 6d | 14dJun 2021 - Jun 2021 |
2025 pullback2025 | -3.06%Dec 2025 | 6d | 3d | 9dNov 2025 - Dec 2025 |
2025 pullback2025 | -2.89%Nov 2025 | 1d | 4d | 5dNov 2025 - Nov 2025 |
Drawdown Indicators
| CNTA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -88.19% | -56.78% | -31.41% |
Max Drawdown (1Y)Largest decline over 1 year | -26.38% | -9.10% | -17.28% |
Max Drawdown (3Y)Largest decline over 3 years | -43.72% | -18.90% | -24.82% |
Max Drawdown (5Y)Largest decline over 5 years | -87.63% | -25.43% | -62.20% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | 0.00% | -1.80% | +1.80% |
Average DrawdownAverage peak-to-trough decline | -51.58% | -10.71% | -40.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.51% | 2.03% | +7.48% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Centessa Pharmaceuticals Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Centessa Pharmaceuticals Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CNTA relative to other companies in the Biotechnology industry. Currently, CNTA has a P/S ratio of 358.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CNTA
Add Centessa Pharmaceuticals Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CNTA